Jean-Paul Clozel, Idorsia CEO (Patrick Straub/Keystone via AP Images)
February 6, 2023 07:35 AM ESTUpdated 08:16 AM
R&D

Idor­si­a's brain bleed drug flunks PhI­II tri­al, a decade af­ter pre­vi­ous flop

Kyle LaHucik

Senior Reporter

Idor­sia’s long jour­ney with cla­zosen­tan came to an abrupt “un­ex­pect­ed re­sult” Mon­day morn­ing with a Phase III flop.

The Swiss bio­phar­ma …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Im­munol­o­gy biotech In­ma­gene to join Nas­daq through re­verse merg­er with what's left of Ike­na

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times